A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 16, 2019

Primary Completion Date

June 18, 2021

Study Completion Date

June 18, 2021

Conditions
Advanced Solid TumorsLymphomaMultiple MyelomaHematologic Malignancies
Interventions
DRUG

AZD0466

"In Arm A, AZD0466 will initially be administered IV over one hour, once weekly to the first cohort of patients. Subsequent cohorts of patients within Arm A are planned to receive sequentially higher doses.~In Arm B, intrapatient dose ramp-ups will involve beginning at a specified starting dose and weekly increasing the dose to a maximum target dose for the cohort."

Trial Locations (5)

37203

Research Site, Nashville

73104

Research Site, Oklahoma City

77030

Research Site, Houston

06510

Research Site, New Haven

02215

Research Site, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY